Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPIKANA: TROP2 CAR-NK Cells in Advanced Solid Tumors
NCT06066424Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2023
- Primary completion
- Apr 2038
- Countries
- 1
01
Overview
Phase 1, open-label trial of TROP2-CAR-NK in solid tumor, non-small cell lung cancer (NSCLC) and breast cancer (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Started Oct 2023; status: recruiting.
02
Drugs
TROP2-CAR-NK
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT06066424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066424.